Blue Water Ventures International, Inc.

Equities

BWVI

US09609E1055

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:05:58 2024-05-14 EDT			5-day change	1st Jan Change
0.0119 ^USD	-4.80%		-37.37%	-80.81%

2023	Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes	CI
2023	Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman	CI

Blue Water Ventures International, Inc. announced that it expects to receive $0.771 million in funding

January 28, 2022

Blue Water Ventures International, Inc. announced that it will receive $771,000 in a round of funding on January 29, 2022. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. The minimum investment accepted from any outside investor is $15,000.

Latest news about Blue Water Ventures International, Inc.

Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes	12-12	CI
Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman	12-12	CI
Blue Water Ventures International, Inc. announced that it expects to receive $5 million in funding	23-09-25	CI
Psycheceutical Bioscience, Inc Announces First Patient Has Been Dosed in Its Phase I Study to Evaluate Its Patented Neurodirectâ„¢ Ketamine Topical Delivery System for the Treatment of Post Traumatic Stress Disorder	23-07-13	CI
Psycheceutical Bioscience, Inc. Announces Publication of Pre-Clinical Observational Data Supports Potential of its NeuroDirect™ Ketamine Topical Cream as Treatment for PTSD	23-03-21	CI
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD	23-02-15	CI
Blue Water Ventures International, Inc. announced a financing transaction	22-02-28	CI
Blue Water Ventures International, Inc. announced that it has received $0.771 million in funding	22-02-16	CI
Blue Water Ventures International, Inc. announced that it expects to receive $0.771 million in funding	22-01-28	CI
Blue Water Ventures International, Inc. completed the acquisition of Psycheceutical, Inc.	22-01-19	CI
Blue Water Ventures International, Inc. signed a non-binding letter of intent to acquire Psycheceutical, Inc.	21-11-02	CI
Blue Water Ventures International Signs Extension on Pulaski Recovery	21-03-17	CI
Blue Water Ventures International, Inc. and Project Partner Endurance Exploration Group, Inc. Announce Preparations for 2019 Operations	19-03-28	CI
Blue Water Ventures International, Inc. Announces the Launch of its Internationally Branded Line of Jewelry with Canada’s SponsorsOne, Inc. and Sponsors One Media, Inc	19-01-02	CI
Blue Water Ventures International, Inc. Signs Brand Development Agreement with SponsorsOne Inc	18-10-30	CI
Blue Water Ventures International, Inc. and Endurance Exploration Group, Inc. Extends the Pulaski Joint Venture Through 2020	18-10-16	CI
Blue Water Ventures International and Endurance Exploration Extend Their Project Recovery Agreement	18-04-25	CI
Ncs and Ngc Announces Selection to Conserve and Grade Ss Pulaski Coins	18-03-27	CI
Blue Water Ventures International Enters into Agreement with Bradford James Partners	17-08-03	CI
Blue Water Ventures International, Inc. Enters Agreement with Under Marine Group, Ltd	17-02-16	CI
Blue Water Ventures International Inc. Announces Formation of New Subsidiary	15-10-01	CI
Blue Water Ventures International, Inc. Announces Directorate Changes	14-04-11	CI
Blue Water Ventures In Negotiations To Acquire Patent Portfolio	13-06-04	CI
Blue Water Ventures International Launches Phase II of Business Model	13-05-09	CI
Blue Water Ventures International, Inc. cancelled the transaction announced on June 29, 2012.	13-01-28	CI

Chart Blue Water Ventures International, Inc.

Duration

Period

Chart Blue Water Ventures International, Inc.

More charts

Company Profile

Psycheceutical Bioscience, Inc. is a bioscience company. The Company is engaged in developing cutting-edge delivery technologies to support safe psychedelic pharmaceutical medicines. The Company's technology is intended to deliver compounds across the blood-brain barrier while bypassing the gastrointestinal (GI) tract and liver, eliminating hallucinogenic effects and vastly reducing exposure to drug toxicities and side effects. The Company's systematic delivery system is designed to use extremely small multi-layered compounds, called Janus particles, to deliver targeted doses of any psychedelic compound directly through the blood-brain barrier, thereby bypassing the liver and reducing toxicity and side effects. The Company's NeuroDirect topical delivery system is a non-systemic delivery technology designed to deliver neuro-active compounds directly into the nerve tissue through topical application at the back of the neck.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BLUE WATER VENTURES INTERNATIONAL, INC.	-80.81%	8.71M
MODERNA, INC.	+29.03%	49.18B
IQVIA HOLDINGS INC.	-0.10%	42.11B
LONZA GROUP AG	+43.45%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B
BIO-TECHNE CORPORATION	+9.06%	13.26B
MEDPACE HOLDINGS, INC.	+30.01%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B

Other Biotechnology & Medical Research